Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
News & Analysis: SpringWorks Therapeutics Inc
The stock climbed after investors saw encouraging signs from a similar program.
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?